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Acyclic nucleoside phosphonates (ANPs), such as (S)-1-[(3-hydroxy-2-phosphonomethoxy)propyl)]cytosine (HPMPC), are
an important group of broad-spectrum antiviral agents with activity against DNA viruses. In this report, we present the in
vitro potencies of novel ANPs against gammaherpesviruses, including Kaposi’s sarcoma-associated herpesvirus, Epstein-
Barr virus (EBV), and three animal gammaherpesviruses. 1-(S)-[3-hydroxy-2-(phosphonomethoxy)propyl]-5-azacytosine
(HPMP-5-azaC), (S)-9-[3-hydroxy-2-(phosphonomethoxy)propyl]-3-deazaadenine (3-deaza-HPMPA), and their cyclic
derivatives have emerged as highly potent antigammaherpesvirus agents. Interestingly, cyclic prodrugs of ANPs exhibited
reduced activities against EBV strain P3HR-1, but not against EBV strain Akata. Cell culture metabolism studies with
HPMPC and cyclic HPMPC revealed that these differences were attributable to an altered drug metabolism in P3HR-1 cells
after EBV reactivation and, more specifically, to a reduced hydrolysis of cyclic HPMPC by cyclic CMP phosphodiesterase.
We did not correlate this effect with phosphodiesterase downregulation, or to functional mutations. Instead, altered cyclic
AMP levels in P3HR-1 cells indicated a competitive inhibition of the phosphodiesterase by this cyclic nucleotide. Finally,
both HPMPC and HPMP-5-azaC emerged as highly effective inhibitors in vivo through significant inhibition of murine
gammaherpesvirus replication and dissemination. With the current need for potent antigammaherpesvirus agents, our
findings underline the requirement of appropriate surrogate viruses for antiviral susceptibility testing and highlight
HPMP-5-azaC as a promising compound for future clinical development.
Kaposi’s sarcoma-associated herpesvirus (KSHV) and Epstein-Barr virus (EBV) are lymphotropic viruses that are character-
ized by their abilities to induce various tumors and lymphoprolif-
erative diseases, particularly in immunocompromised patients (1,
2). The lack of permissive replication systems and appropriate in
vivo animal model systems have hampered the study of both
KSHV and EBV (3, 4). Experiments involving the lytic cycle re-
quire reactivation of KSHV and EBV in latently infected B cells by
using phorbol esters or IgG (5–7). Alternatively, the use of closely
related animal gammaherpesviruses, such as murine gammaher-
pesvirus 68 (MHV-68), herpesvirus saimiri (HVS), and rhesus
rhadinovirus (RRV), can overcome these difficulties and are com-
monly used as surrogate viruses to study EBV and KSHV patho-
genesis. These viruses are capable of replicating to high titers and
form plaques in different cell types (8–10). Moreover, infection of
laboratory mice with MHV-68 has been generally used as a small
animal model that offers relevant aspects for KSHV and EBV (9,
11). Major features of gammaherpesvirus pathogenesis are similar
in humans and mice, including the initial acute respiratory infec-
tion and the establishment of viral latency in B cells (12).
The antiviral drug class of acyclic nucleoside phosphonates
(ANPs) encompasses (S)-1-[(3-hydroxy-2-(phosphomethoxy)
propyl)]cytosine (HPMPC, or cidofovir), formally licensed for
the treatment of cytomegalovirus (CMV) retinitis in AIDS pa-
tients, as well as 9-[2-(phosphonomethoxy)ethyl]adenine (PMEA,
or adefovir) and (R)-9-[2-(phosphonomethoxy)propyl]adenine
(PMPA, or tenofovir), which are both active against hepatitis B
virus (HBV) and human immunodeficiency virus (HIV) infec-
tions. These nucleotide analogs contain a phosphonate group that
is linked to the acyclic nucleoside moiety through a stable POC
bond, which cannot be cleaved by cellular esterases (13). ANPs need
to be phosphorylated by cellular kinases to their diphosphate forms to
become biologically active, and their selectivity is based on inhibition
of reverse transcriptase and/or viral DNA polymerase (14).
New derivatives of ANPs containing a 3-hydroxy-2-(phospho-
nomethoxy)propyl (HPMP) group or a 2-phosphonomethoxy-
ethyl (PME) group as an acyclic nucleoside moiety have been de-
veloped. These analogs are derivatives of diaminopurine (i.e.,
HPMPDAP and PMEDAP) or diaminopyrimidine (i.e., HPMPO-
DAPy and PMEO-DAPy), in which the base moiety is linked via
an ether linkage to the aliphatic phosphonate side chain through
an oxygen atom at the C-6 position of the pyrimidine ring. A new
generation of ANPs encompasses HPMP derivatives with a 5-aza-
cytosine (5-azaC) moiety, with HPMP-5-azaC the leading com-
pound. In addition, cyclic prodrugs of ANPs have been developed,
such as cyclic HPMPC, which was reported to exhibit similar an-
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tiviral activity as HPMPC but reduced nephrotoxicity (15). These
novel ANPs have been shown to exert antiherpesvirus activity and
yield great potential for the treatment of various DNA virus and
retrovirus infections (13, 16, 17). However, their potencies against
gammaherpesviruses have not yet been investigated.
Although no antiviral drugs are currently licensed for treat-
ment of KSHV or EBV infections, several antiherpetic agents have
been shown to inhibit these viruses in vitro, particularly those that
target the viral DNA polymerase, such as acyclovir, ganciclovir,
foscarnet, and HPMPC (18–22). Besides the inhibition of virus
lytic replication, HPMPC elicits antitumor activity by induction
of apoptosis, and this effect was also demonstrated against naso-
pharyngeal carcinoma (associated with EBV infection) xenografts
in nude mice (23, 24). On the other hand, maribavir (MBV), a
benzimidazole riboside, has potent antiviral activity against EBV
and is in the late stage of clinical development for human CMV
diseases. The mechanism of action remains partially unclear, but it
was recently shown to involve the inhibition of the viral protein
kinase BGLF4 and thus is independent of the viral DNA polymer-
ase (25). The risk of developing virus-associated diseases is higher
in immunocompromised patients with high EBV or KSHV loads,
and therefore reducing viral loads by a combination of therapy
with antivirals may have positive effects on the onset and disease
progression (26, 27). The use of antivirals for the treatment of
infectious mononucleosis (IM) in immunocompetent patients is
still debatable, because the symptoms of IM are subtle at onset and
the disease has a long incubation period (4 to 6 weeks), resulting in
a late diagnosis (28). However, in patients with severe EBV-in-
duced infectious mononucleosis, antiviral therapy may be consid-
ered as an adjunct to corticosteroid treatment (29). New and
promising therapeutic approaches to EBV and KSHV-associated
malignancies are under investigation and consist of the induction
of virus replication followed by administration of viral DNA poly-
merase inhibitors, as well as targeting viral latency (30, 31).
In this study, we evaluated the in vitro activities and selectivities
of various ANPs, including cyclic HPMP analogs, against gamma-
herpesvirus replication. Interestingly, the study revealed notable
differences in the anti-EBV activities between the noncyclic and
cyclic forms of ANPs in P3HR-1 cells, but not in Akata cells. Drug
metabolism studies with HPMPC and cyclic HPMPC were per-
formed in these cell lines, and the involvement of cyclic AMP
(cAMP) and the cellular 2=-3=-cyclic nucleotide 3=-phosphodies-
terase (CNP; EC 3.1.4.37) in the altered drug metabolism in in-
duced P3HR-1 cells was investigated. Finally, the antiviral efficacy
of a potent ANP, HPMP-5-azaC, was examined in a mouse model
for gammaherpesvirus infection.
MATERIALS AND METHODS
Cells and viruses. KSHV-infected BCBL-1 cells (NIH AIDS Research and
Reference Reagent Program), JSC-1 cells (ATCC CRL-2769), EBV-in-
fected P3HR-1 cells (ATCC HTB-62), and Akata 2000 cells (kindly pro-
vided by P. J. Farrell, Imperial College Faculty of Medicine, St. Mary’s
Campus, London, United Kingdom) were cultured in RPMI 1640 me-
dium (Life Technologies Europe BV, Ghent, Belgium). Murine fibroblasts
(NIH 3T3 cells; ATCC CRL-1685), owl monkey kidney cells (OMK;
ATCC CRL-1556), and rhesus monkey fibroblasts (RF; kindly provided
by S. Wong, Oregon Health and Science University, Beaverton, OR) were
grown in Dulbecco’s modified eagle’s medium (DMEM). All media were
supplemented with 10% heat-inactivated fetal calf serum (FCS), 2 mM
L-glutamine, 1% nonessential amino acids, 1% sodium pyruvate, and 1%
HEPES. Cultures were incubated at 37°C and 5% CO2. The following viral
strains were used: MHV-68 clone G2.4 (provided by A. A. Nash, Edin-
burgh, United Kingdom); HVS strain C-488 (ATCC VR-1414); RRV
strain 17577 (kindly provided by S. Wong, Oregon Health and Science
University, Beaverton, OR). These strains were grown in NIH 3T3, OMK,
and RF cells, respectively.
Compounds. The sources of the compounds were as follows:
HPMPC, cyclic HPMPC, and PMEA were obtained from Gilead Sciences,
Foster City, CA. The following ANPs (and their cyclic analogs) were syn-
thesized at the Institute of Organic Chemistry and Biochemistry, Prague,
Czech Republic: HDP-HPMPC (hexadecyloxypropyl-HPMPC), HPMP-
5-azaC, HPMPA, 3-deaza-HPMPA, 7-deaza-HPMPA, HPMPDAP, HPMPO-
DAPy, 9-[2-(phosphonomethoxy)ethyl]-2,6-diaminopurine (PMEDAP),
and 2,4-diamino-6-[2-(phosphonomethoxy)ethoxy]pyrimidine (PMEO-
DAPy). The compound structures were previously published (32).
[5-3H]HPMPC (MT-833; specific activity, 26.0 Ci/mmol) and cyclic
[5-3H]HPMPC (MT-1713; specific activity, 23 Ci/mmol) were custom
synthesized by Moravek Biochemicals (Brea, CA).
KSHV and EBV antiviral assays. For the antiviral assays, cells were
seeded in 48-well plates at a density of 3 105 cells/ml (BCBL-1) or 106
cells/ml (JSC-1, Akata, and P3HR-1). Virus replication was induced by
addition of 20 ng/ml 12-O-tetradecanoylphorbol 13-acetate (TPA;
Sigma) to the cells or 0.1% rabbit anti-human IgG (A0423; Dako) to Akata
cells. After 24 h of induction, cells were washed and resuspended in fresh
medium in the presence of various concentrations of antiviral drugs. At
day 5 postinduction, total DNA was extracted (QIAamp DNA kit; Qiagen,
Benelux BV, Venlo, Netherlands), and viral DNA was quantified by real-
time quantitative PCR (qPCR) using an ABI Prism 7500 sequence detec-
tion system (Life Technologies). The sequences of the PCR primers for the
detection of the target genes of KSHV (ORF73) and EBV (BNRF1) have
been described elsewhere (18). The 50% and 90% effective concentrations
(EC50 and EC90) were calculated by using regression analysis. These EC50
and EC90 values are the concentrations required to reduce KSHV and EBV
DNA synthesis in TPA-induced cells by 50% and 90%, respectively.
CPE reduction assays. NIH 3T3, OMK, and RF cells were grown in
96-well plates and infected with MHV-68, HVS, or RRV, respectively, at a
multiplicity of infection of approximately 0.02 PFU/cell. Following 2 h of
virus adsorption at 37°C, serial dilutions of test compounds were added in
duplicate. Viral infections and dilutions of the drugs were performed in
DMEM containing 2% FCS. At day 5 (for MHV-68 and HVS) or 8 (for
RRV) postinfection (p.i.), the cytopathic effect (CPE) was evaluated mi-
croscopically, and EC50s were determined as the compound concentra-
tions required to reduce the virus-induced CPE by 50%.
Cytotoxicity assays. The cytotoxicity of the antiviral compounds was
determined based on the inhibition of cell growth. In 48-well plates, un-
induced BCBL-1 and P3HR-1 cells were grown in culture medium in the
presence or absence of serial dilutions of the test compounds. After 3 days
of incubation, cells were counted with a Coulter counter (Analis, Namur,
Belgium). In 96-well plates, NIH 3T3, OMK, and RF cells were grown at a
density of 3 103 cells/well. The next day, various concentrations of the
compounds were added. The cells were counted after 3 days of incubation.
The 50% cytostatic concentrations (CC50s) were defined as the concen-
tration of compound required to reduce cell growth by 50%. Selectivity
indices were determined by calculation of the CC50/EC50 ratio.
Intracellular metabolism of HPMPC and cyclic HPMPC. P3HR-1
and Akata cells were seeded at a density of 1.5 106 cells/ml and grown in
the presence or absence of 20 ng/ml TPA or 0.1% IgG. The next day, 10
Ci [5-3H]HPMPC] or cyclic [5-3H[HPMPC] was added to the medium.
Unradiolabeled compound was added to obtain a final concentration of
HPMPC or cyclic HPMPC of 10 M. After 24, 72, or 120 h, cell extracts
were obtained as previously described (33). Briefly, cells were washed
three times with ice-cold serum-free medium and centrifuged at 13,000
rpm for 10 min, and cell pellets were extracted with 300 l ice-cold 67%
methanol in water. Extracts were incubated for 10 min on ice and centri-
fuged at 13,000 rpm for 10 min. Supernatants and cell pellets were stored
at20°C until further use. For high-performance liquid chromatography
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(HPLC) analysis, 200-l aliquots of the supernatants were injected onto
an anion-exchange Partisphere SAX column (dimensions, 4.6 mm by 125
mm; Whatman, Maidstone, United Kingdom). The buffer composition
and gradient system were the same as described previously (33). One-
minute fractions of the eluate were collected, mixed with Hisafe 3 cocktail
(PerkinElmer, Waltham, MA), and analyzed for radioactivity in a scintil-
lation counter. The different metabolites were identified based on their
retention times.
To determine incorporation levels of [5-3H]HPMPC and cyclic [5-
3H]HPMPC into total cellular DNA, the methanol-insoluble pellets were
digested in 500 ml 5 N sodium hydroxide during 24 h of incubation at
37°C. After neutralization with 500 ml 5 N hydrochloride, digested sam-
ples were mixed with Hisafe 3 cocktail and analyzed for total radioactivity.
Western blotting. Western blot assays were performed by using
mouse monoclonal antibody specific to CNP (1:500 dilution; ab6319;
Abcam, Cambridge, MA) and goat anti--actin (1:500; sc1615; Santa
Cruz Biotechnology, Santa Cruz, CA) as the primary antibodies and poly-
clonal goat anti-mouse antibody (1:10,000; P0447; Dako, Belgium) or
polyclonal rabbit anti-goat antibody (1:10,000; P0449; Dako) conjugated
to horseradish peroxidase as the secondary antibodies. Films were
scanned, and quantification of the bands was obtained by applying ImageJ
software. The area under the time-concentration curve for CNP was nor-
malized to that of -actin.
Sequencing. After extracting total RNA from P3HR-1 and Akata cells
with TRIzol reagent (Life Technologies) and an RNeasy minikit (Qiagen),
cDNA was obtained using a first-strand cDNA synthesis kit (GE Health-
care). The entire CNP mRNA was amplified by PCR by using FastStart
high-fidelity DNA polymerase (Roche Applied Science, Mannheim, Ger-
many) following the manufacturer’s instructions. PCR products were pu-
rified with a QIAquick purification kit (Qiagen), and the amplicons were
sequenced using a cycle sequencing BigDye Terminator kit version 3.1 on
an ABI 3730 sequencing system (Applied Biosystems) and a set of primers
spanning the entire coding region of the CNP gene. The sequencing re-
sults were computer assembled and compared with the sequence of the
reference sequence (NM_033133.4) by using the software SeqScape ver-
sion 2.7 (Applied Biosystems).
Quantification of cAMP. P3HR-1, Akata, JSC-1, and BCBL-1 cells
were induced with 20 ng/ml TPA or 0.1% IgG. After 24, 72, or 120 h, the
concentration of cAMP was quantified in the cell lysates by using a cAMP
(direct) enzyme immunoassay kit according to the manufacturer’s in-
structions (Enzo Life Sciences, Antwerp, Belgium).
Animal studies. All animal work was approved by the KU Leuven
Ethics Committee for Animal Care and Use (permit number P097-2010).
All animal experiments were conducted in accordance with the Belgian
and European guidelines for the protection of vertebrate animals used for
experimental and other scientific purposes.
BALB/c mice (age, 4 weeks) were inoculated intranasally with 10,000
PFU MHV-68 under anesthesia with ketamine-xylazine in saline.
HPMPC and HPMP-5-azaC were administered intraperitoneally (i.p.) at
a dose of 25 mg/kg of body weight/day for 5 consecutive days (starting 2 h
p.i.). At days 6 and 12 p.i., five mice per group were sacrificed by injection
of pentobarbital, and lungs, mediastinal lymph nodes (MLNs), and
spleens were harvested. Tissue sections were stored (i) at20°C in phos-
phate-buffered saline for DNA extraction, (ii) at 80°C in RNAlater
(Ambion) for RNA extraction, and (iii) fixed in 10% buffered formalin.
Tissues were embedded in paraffin, and 5-m sections were stained with
hematoxylin-eosin for histopathological examination.
Quantification of viral DNA load and determination of relative ORF73
and gB expression levels in the tissues were performed as previously de-
scribed (34). Briefly, tissues were homogenized and DNA was extracted by
using a QIAamp DNA minikit (Qiagen), and DNA was quantified by
qPCR. RNA was extracted by using a combination of TRIzol reagent (In-
vitrogen) and an RNeasy minikit (Qiagen). One-step reverse transcrip-
tion-qPCR was performed using a TaqMan RNA-to-CT 1-step kit (Ap-
plied Biosystems) for relative quantitation of RNA.
RESULTS
In vitro antiviral activities of ANPs against gammaherpesvi-
ruses. The activities and selectivities of ANPs against KSHV, EBV,
MHV-68, HVS, and RRV are summarized in Table 1 and Table 2.
Overall, HPMP derivatives were potent inhibitors of KSHV repli-








b SIcEC50 EC90 EC50 EC90
HPMPC 1.3 0.29 2.2 1.3 609 92 468 1.9 1.6 20 1.6 500 263
Cyclic HPMPC 2.4 1.0 3.7 3.7 589 121 245 41 24 256 286 500 15
HDP-HPMPC 0.7 0.1 59 18 125 179 0.3 0.2 5.2 5.9 125 417
HPMP-5-azaC 0.7 0.4 9.6 7.1 500 714 3.2 1.8 50 40 500 156
Cyclic HPMP-5-azaC 3.1 0.8 4.6 11 462 31 149 1.1 0.2 7.6 9.2 500 455
HPMPA 0.7 0.7 96 406 3 580 3.6 5.3 36 36 500 139
Cyclic HPMPA 0.7 0.4 112 428 189 611 39 25 312 217 500 13
3-Deaza-HPMPA 0.3 0.2 3.0 1.7 97 46 323 0.7 0.7 28 22 500 714
Cyclic 3-deaza-HPMPA 1.8 0.4 3.9 3.2 84 70 47 39 9 496 127 500 139
7-Deaza-HPMPA 5.0 0.3 12 6.6 30 10 6 5.3 9.3 66 0 470 89
Cyclic 7-deaza-HPMPA 1.4 5.6 2.5 0.4 116 25 83 239 500 500 2
HPMPDAP 0.9 0.3 31 22 459 157 510 38 28 336 500 13
Cyclic HPMPDAP 2.0 1.3 7.3 6.7 107 47 54 500 500 500 1.0
HPMPO-DAPy 5.1 1.4 17 0 139 129 27 59 24 500 500 8
Cyclic HPMPO-DAPy 111 20  500 627 211 6 500 500 500 1.0
PMEA 44 15 172 44 26 1 13 3.3 55 29 500 38
PMEDAP 16 7.6 174 14 7 1 7.6 4.2 90 73 500 66
PMEO-DAPy 12 5.0 159 27 11 2 5.0 2.3 23 3.8 500 100
a The concentrations required to reduce KSHV or EBV DNA synthesis in TPA-stimulated BCBL-1 or P3HR-1 cells by 50 or 90%. Means standard deviations are shown where
applicable.
b The concentration required to reduce the growth of uninduced BCBL-1 or P3HR-1 cells by 50%. Means standard deviations are shown where applicable.
c The selectivity index (ratio of the CC50 to the EC50).
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cation in BCBL-1 cells. With the exception of cyclic HPMPO-
DAPy, EC50s ranged from 0.3 to 5.1 M. The highest anti-KSHV
activity was found with 3-deaza-HPMPA. HPMP-5-azaC dis-
played the highest selectivity, with a selectivity index (SI) of714
and an EC90 of 9.6 M. In contrast, PMEA, PMEDAP, and
PMEO-DAPy demonstrated relatively weak antiviral activities
and no selectivity against KSHV in BCBL-1 cells.
Compared to HPMPC (EC50, 1.9 M), HDP-HPMPC and
3-deaza-HPMPA were more active against EBV strain P3HR-1,
with EC50s of 0.3 M and 0.7 M, respectively. HPMPC, HPMP-
5-azaC, cyclic HPMP-5-azaC, HPMPA, and 7-deaza-HPMPA
showed similar anti-EBV activities, with EC50s ranging from 1.9 to
5.3 M. Weak or no inhibition of EBV replication was observed
for HPMPDAP, HPMPO-DAPy, or cyclic HPMP derivatives,
with the exception of cyclic HPMP-5-azaC. PMEA, PMEDAP,
and PMEO-DAPy showed moderate EC50s, in the range of 5 to
13 M.
Regarding the inhibition of MHV-68 replication, HPMPC,
HPMP-5-azaC, HPMPA, and their cyclic forms exhibited EC50s in
the range of 1.4 to 4.6 M and SIs between 10 and 272. The other
drugs (except for cyclic 7-deaza HPMPA, cyclic HPMPDAP, and
cyclic HPMPO-DAPy) were even more inhibitory against
MHV-68 replication than HPMPC and HPMPA, with EC50s
of1 M.
HVS was selectively inhibited by HPMPC (SI, 143), its
5-azaC derivative (SI, 348), HPMPA (SI, 99), and its 3-deaza de-
rivative (SI, 119), as well as by their respective cyclic forms. Poor
activities and selectivities were obtained for the other ANP deriv-
atives.
The replication of RRV was markedly inhibited by HPMPC,
HPMP-5-azaC, and 3-deaza- and 7-deaza-HPMPA, as well as
their cyclic derivatives, with EC50s ranging from 0.2 to 1.8 M.
Moderate activities but high selectivities were found for HPMP-
DAP, HPMPO-DAPy, and their cyclic forms. Poor activities and
no selectivity were determined for PMEA, PMEDAP, and PMEO-
DAPy against this virus.
Among the ANPs tested against the five gammaherpesviruses, the
highest selectivity indices were found for HPMPC, HPMP-5-azaC,
3-deaza-HPMPA, and their cyclic derivatives. Compared to BCBL-1,
P3HR-1, OMK, and RF cells, NIH 3T3 cells appeared to be more
susceptible to the cytostatic effects of ANPs, and therefore relatively
lower SIs were determined against MHV-68 for NIH 3T3 cells.
Reduced activities of cyclic HPMP derivatives against EBV in
P3HR-1 cells. (i) Activities of cyclic and noncyclic forms of
ANPs in different EBV- and KSHV-positive B-cell lines. Unlike
what was seen with KSHV, the cyclic prodrugs of HPMPC,
HPMPA, 3-deaza-HPMPA, 7-deaza-HPMPA, HPMPDAP, and
HPMPO-DAPy were 10- to 50-fold less active against EBV than
their noncyclic forms, e.g., the EC50s of HPMPC and cyclic
HPMPC were 2 and 41 M in P3HR-1 cells, respectively. Among
the cyclic HPMP derivatives, cyclic HPMP-5-azaC was found to
be an exception, showing a similar EC50 as HPMP-5-azaC against
the EBV P3HR-1 strain (1 and 3 M, respectively).
To determine whether these differences in antiviral activity
reflected a particular feature of EBV and/or the P3HR-1 cell line,
we evaluated the inhibitory activities of several ANPs and their
cyclic forms in the EBV-positive Akata cell line, as well as in the
KSHV-positive JSC-1 cell line (Fig. 1). No discrepancies in antivi-
ral activities between noncyclic versus cyclic forms of ANPs were
noticed in Akata cells, e.g., the EC50s determined for HPMPC and
cyclic HPMPC were 5.4 and 8.7 M, respectively. In addition, we
found similar activities for the cyclic and noncyclic compounds
against KSHV in JSC-1 cells. Thus, the reduced antiviral activities
of cyclic HPMP derivatives were only observed against the EBV
P3HR-1 strain. We hypothesized that an impaired conversion of
the cyclic forms into their parent counterparts, e.g., cyclic
HPMPC into HPMPC, was responsible for the reduced activities
of the cyclic prodrugs against EBV strain P3HR-1.
(ii) Metabolism of HPMPC and cyclic HPMPC in P3HR-1
and Akata cells. After cellular uptake, cyclic HPMPC is efficiently
converted into its parent form HPMPC by the phosphodiesterase
CNP (35). Further metabolic conversion of HPMPC leads to





b (M) SIc EC50
a (M) CC50
b (M) SIc EC50
a (M) CC50
b (M) SIc
HPMPC 1.6 0.2 98 25 61 3.5 2.2 500 143 0.2 0.1 578 295 2,627
Cyclic HPMPC 2.5 1.2 680 199 272 1.4 0.7 500 357 0.2 0 500 2,941
HPMP-5-azaC 1.8 1.4 93 36 52 2.1 1.8 732 130 348 0.2 0.01 539 125 2,695
Cyclic HPMP-5-azaC 4.6 2.9 195 114 42 1.5 0.4 275 53 183 1.1 0.8 313 164 285
HPMPA 3.0 3.3 30 13 10 4 2.3 396 241 99 0.3 0.3 353 3 1,177
Cyclic HPMPA 1.4 0.4 63 25 45 8.4 4.2 500 60 0.3 0 182 109 607
3-Deaza-HPMPA 0.2 0.1 17 13 85 1.0 0.3 119 63 119 0.3 0.03 116 76 387
Cyclic 3-deaza-HPMPA 0.4 0.3 49 7 123 2.8 1.4 538 289 192 1.4 2.1 190 32 136
7-Deaza-HPMPA 0.7 0.7 4.6 1.3 7 56 33 500 9 0.7 0.3 46 13 66
Cyclic 7-deaza-HPMPA 13 6 137 46 11 88 74 500 6 1.8 0 637 320 354
HPMPDAP 0.9 0.3 25 14 28 28 6 500 18 2.8 3.1 500 179
Cyclic HPMPDAP 17 0 7.7 6.3 1 67 13 500 3 3.3 1.7 500 152
HPMPO-DAPy 0.1 0.07 1.0 1.0 10 68 17 500 7 5.2 0.64 500  96
Cyclic HPMPO-DAPy 6.7 0 211 57 31 215 10 500 2 15 3.7 476 238 32
PMEA 0.7 0 12 5 17 172 81 500 3 238 55 586 187 2
PMEDAP 0.1 0.03 2.8 1.4 28 59 7.1 500 8 73 7.0 500 7
PMEO-DAPy 0.1 0.08 2.3 1.5 23 413 208 583 102 1 242 121 242 87 1
a Concentration required for 50% inhibition of CPE. Values are means standard deviations where applicable.
b Concentration required to reduce the growth of NIH 3T3, OMK, and RF cells by 50%. Values are means standard deviations where applicable.
c Ratio of the CC50 to the EC50.
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the production of three metabolites: HPMPC monophosphate
(HPMPCp), HPMPC diphosphate (HPMPCpp), and the choline
adduct (HPMPCp-choline), which is the intracellular reservoir
form of HPMPC (Fig. 2A). We studied the metabolism of HPMPC
and cyclic HPMPC in the two EBV-infected cell lines. A kinetic
study was performed to determine the concentrations of drug me-
tabolites after 24, 72, and 120 h of incubation with 10 M [5-
3H]HPMPC or cyclic [5-3H]HPMPC in P3HR-1 and Akata cells
that were induced into the EBV lytic cycle by either TPA or IgG
(Fig. 2C). A representative chromatogram of HPMPC and cyclic
HPMPC metabolism at 120 h is shown in Fig. 2B. Under the assay
conditions used, cyclic HPMPC coeluted with HPMPCp-choline
(retention time, 1 to 3 min). As a consequence, the radioactivity
results in the first 3 min of the chromatograms obtained from
cells incubated with cyclic HPMPC showed a mixture of cyclic
HPMPC and HPMPCp-choline.
The metabolic profiles of HPMPC versus cyclic HPMPC
showed interesting differences in induced P3HR-1 cells, as well as
between P3HR-1 and Akata cells (Fig. 2C). The total amount of
radioactivity of all metabolites after incubation with HPMPC was
markedly increased in P3HR-1 cells compared to Akata cells (7 to
18 pmol/106 cells versus 1 to 3 pmol/106 cells). Also, after addition
of HPMPC or cyclic HPMPC to Akata cells, similar levels of total
radioactivity were seen at 24, 72, and 120 h. In contrast, following
incubation of P3HR-1 cells with cyclic HPMPC, the total radioac-
tivity was 2- to 4-fold reduced from that for the cells incubated
with HPMPC (e.g., concentrations at 72 h after addition of cyclic
HPMPC or HPMPC were 4 pmol/106 cells or 18 pmol/106 cells,
respectively).
We observed another striking dissimilarity in the metabolism
of cyclic HPMPC in induced P3HR-1 at the three designated time
points. As shown in Fig. 2C, the concentrations of metabolites that
were formed in these cells were low when cyclic HPMPC was
added, compared to HPMPC addition. After 72 and 120 h of in-
cubation with cyclic HPMPC, the relative proportion of drug me-
tabolites did not increase. Unlike P3HR-1 cells, Akata cells were
found to produce relatively similar concentrations of drug metab-
olites when cells were incubated with HPMPC or with cyclic
HPMPC. Taken together, these findings pointed toward an im-
paired metabolism of cyclic HPMPC in P3HR-1 cells, in particu-
lar, the conversion of cyclic HPMPC into HPMPC.
A similar experiment was conducted in latently infected P3HR-1
and Akata cells, which were incubated with [5-3H]HPMPC or cyclic
[5-3H]HPMPC during 72 h, since the altered drug metabolism
was the most pronounced at this time point in activated cells. Both
latently EBV-infected cell lines had comparable amounts of total
radioactivity after incubation with either HPMPC or cyclic
HPMPC, i.e., 3 to 4 pmol/106 cells (Fig. 2D). Although, the me-
tabolite concentrations in P3HR-1 cells were slightly lower after
addition of cyclic HPMPC than with HPMPC, we did not consider
that the metabolism of cyclic HPMPC was altered, such as in in-
duced P3HR-1 cells. The drug metabolites produced in Akata cells
incubated with both compounds accounted for similar relative
concentrations. The amount of the active metabolite HPMPCpp
was shown to be slightly lower in both cell lines when incubated
with cyclic HPMPC than with HPMPC.
We further examined the incorporation of radioactivity into
total cellular DNA after incubating the cells with cyclic HPMPC or
HPMPC. As shown in Fig. 2E, the incorporated radioactivity after
72 h of incubation of P3HR-1 cells with cyclic HPMPC was 4-fold
above the cultures receiving HPMPC. In contrast, in Akata cells,
DNA incorporation levels were comparable after incubation with
cyclic HPMPC or HPMPC. Both latently infected cell lines
showed somewhat reduced incorporation of HPMPC into DNA
after addition of cyclic HPMPC, but no differences in drug incor-
poration were observed in P3HR-1 versus Akata cells. Hence, the
altered drug metabolism was exclusively observed in induced
P3HR-1 cells.
(iii) Characterization of CNP expression in EBV- and KSHV-
infected cells. The cellular CMP phosphodiesterase CNP has been
reported to convert cyclic HPMPC into HPMPC (35). To examine
whether reduced expression of CNP may be responsible for the
altered cyclic HPMPC metabolism in induced P3HR-1 cells, we
performed Western blot analysis to determine the protein levels of
this enzyme in different B-cell lines, including P3HR-1 and Akata,
as well as two KSHV-positive cell lines, BCBL-1 and JSC-1. Rela-
tive quantification of the band intensities showed no significant
differences in the amount of CNP between the different cell lines,
neither in latently infected cells nor in cells induced into the virus
lytic cycle (Fig. 3). Even though there was a trend toward an ele-
vated CNP protein level in JSC-1 cells, this difference was not
significant.
(iv) Sequence analysis of CNP cDNA derived from different
B-cell lines. We performed genotypic analysis of the cDNA for
CNP obtained from P3HR-1, Akata, BCBL-1, and JSC-1 cells to
identify any mutations that could potentially affect the enzymatic
activity. In one allele of the coding sequence of CNP derived from
P3HR-1 cells, a missense mutation was identified at nucleotide
position 620, resulting in a Q207R amino acid change. This mu-
tation was mapped to the CNPase domain of the protein but was
previously reported as a single-nucleotide polymorphism (refer-
FIG 1 Inhibitory effects of HPMP derivatives against KSHV and EBV repli-
cation in different B-cell lines. EC50s of ANPs against KSHV in BCBL-1 and
JSC-1 cells, and against EBV in P3HR-1 and Akata cells were plotted as the
mean of at least three independent experiments the standard deviation. The
EC50 was defined as the concentration required for 50% inhibition of viral
DNA load.
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ence SNP rs34353668). Therefore, this amino acid change is not
expected to affect the enzymatic activity.
(v) cAMP levels in latently infected cells and in cells induced
into the virus lytic cycle. Mendel et al. previously demonstrated
that cyclic HPMPC is an efficient substrate for CNP and that it
competes with the natural substrates cAMP and cCMP (35).
Therefore, we hypothesized that enhanced conversion of cAMP
might compete with cyclic HPMPC for hydrolysis by CNP in
P3HR-1 cells, but not in Akata cells. Therefore, we performed an
enzyme-linked immunosorbent assay (ELISA) to quantify the in-
tracellular cAMP levels in latently infected cells and in induced
P3HR-1, Akata, BCBL-1, and JSC-1 cells at 24, 72, and 120 h
(Fig. 4). The levels of cAMP were comparable in latently infected
Akata cells, BCBL-1 cells, and JSC-1 cells, and similar levels were
also found after induction of the virus lytic cycle, with mean levels
ranging from 5 to 20 pmol/106 cells. In contrast, cAMP levels in
latently infected P3HR-1 cells were as high as 70 pmol/106 cells,
but after EBV reactivation, the cAMP levels decreased to approx-
imately 10 pmol/106 cells.
The reduction of intracellular cAMP concentration, as ob-
served after reactivation of EBV in P3HR-1 cells, may be the result
of increased cAMP efflux from the cells and/or its increased hy-
drolysis. We quantified the extracellular cAMP levels in P3HR-1
cells, yet observed no differences in cAMP levels between the la-
tent and lytic states (approximately 10 pmol/106 cells/ml) (Fig. 4).
Thus, the decrease in the intracellular cAMP level after EBV reac-
tivation in P3HR-1 cells appears to result from enhanced degra-
dation of cAMP to AMP by phosphodiesterases. Supernatants of
FIG 2 Metabolism of [5-3H]HPMPC and cyclic [5-3H]HPMPC in P3HR-1 and Akata cells after 120 h. (A) Activation pathway for HPMPC and cyclic HPMPC.
CNP, cellular 2=,3=-cyclic nucleotide 3=-phosphodiesterase. (B) Representative HPLC result showing the metabolism of 10 M [5-3H]HPMPC and cyclic
[5-3H]HPMPC in induced P3HR-1 and Akata cells after 120 h of exposure to the indicated compound. The arrows point to the different metabolites of HPMPC
and cyclic HPMPC. Note the differences between values on the y axis. (C) At the designated time points, intracellular concentrations of HPMPC, HPMPCp,
HPMPCpp, HPMPp-choline, and a mixture of cyclic HPMPC and HPMPCp-choline were determined in P3HR-1 and Akata cells after EBV reactivation. The
means of two independent experiments were plotted. (D) Intracellular concentrations of HPMPC metabolites in latently infected cells at 72 h after addition of
HPMPC or cyclic HPMPC were plotted as the means of two independent experiments. (E) Incorporation of HPMPC into DNA of P3HR-1 and Akata cells in the
latent and lytic stages of the virus life cycle after 72 h of incubation.
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BCBL-1, JSC-1, and latently infected Akata cells showed compa-
rable cAMP levels, ranging from 1 to 4 pmol/106 cells/ml. The high
cAMP levels obtained in IgG-induced Akata cells were due to
interference of the IgG with the ELISA, as reported by the man-
ufacturer. To confirm this, we included an IgG control sample
consisting of medium and IgG, and it showed cAMP levels
similar to those found in the supernatants of Akata cells in the
lytic state.
Efficacy of HPMPC and HPMP-5-azaC treatment in MHV-
68-infected mice. In this study, we showed that HPMP-5-azaC
possesses potent in vitro activity and selectivity against all five
gammaherpesviruses tested and, moreover, its cyclic derivative
was highly active against EBV in P3HR-1 cells. Therefore, we eval-
uated the in vivo efficacies of HPMPC and HPMP-5-azaC in
BALB/c mice intranasally infected with MHV-68. Drug efficacy
was evaluated at two time points to determine the inhibition of
acute MHV-68 replication in the lungs (at day 6 p.i.), as well as the
prevention of establishment of viral latency in the spleen at an
early time point (at day 12 p.i.). Both time points were selected
based on previous kinetic experiments in which latent (ORF73)
and lytic (gB) MHV-68 gene expression was determined in this
mouse model (34). Infected mice were treated i.p. with 25 mg per
kg per day of HPMPC or HPMP-5-azaC during 5 consecutive
days. Animals were sacrificed at day 6 or day 12 p.i., and viral DNA
loads were recorded for lungs, spleens, and MLNs. A significant
decrease in MHV-68 DNA copies was observed in the lungs of
HPMPC- and HPMP-5-azaC-treated mice at day 6 p.i. and day 12
p.i. (Fig. 5A). At day 12 p.i., infected untreated animals showed
high numbers of viral DNA copies in MLNs (ranging from 105 to
106 copies) and spleens (104 to 105 copies/mg). In contrast, no
viral DNA was detected in these tissues in mice treated with
HPMPC or HPMP-5-azaC.
We further evaluated the impact of antiviral treatment on the
lytic and latent stages of MHV-68 infection at the end of treatment
(day 6 p.i.) and after treatment (day 12 p.i.) by determining the
ORF73 (latent) and gB (lytic) gene expression levels in lungs and
spleen tissues. Compared to the untreated infected control, drug
treatment resulted in a 300-fold (HPMPC) and 20-fold (HPMP-
5-azaC) decrease in gB expression at day 6 p.i. in lung tissue (Fig.
5A). Both drugs reduced the levels of the ORF73 transcript by
300-fold at this time point. No gB expression was found in the
lungs of HPMPC-treated mice at day 12 p.i., whereas two out of
five HPMP-5-azaC-treated mice showed low gB expression levels.
ORF73 expression was reduced by approximately 10-fold in the
lungs of treated mice at day 12 p.i. compared to the untreated
controls. In the spleen tissue, the gB and ORF73 transcripts were
not detected in drug-treated mice.
Histological examination revealed the presence of an in-
flammatory response in the lungs of infected mice at day 6 p.i.
that was characterized by an increased interstitial cellularity in
perivascular and peribronchial locations (Fig. 5B). At day 12
p.i., the inflammation in the lungs was dominated by mononu-
clear inflammatory cells. Following HPMPC or HPMP-5-azaC
FIG 3 Expression of CNP in EBV- and/or KSHV-positive cells. The Western
blot shows CNP in induced and latently infected B cells at 120 h (upper panel)
and band intensities relative to actin (lower panel).
FIG 4 Intracellular and extracellular cAMP levels in P3HR-1, Akata, BCBL-1,
and JSC-1 cells. Cells were cultured for 24, 72, or 120 h in the presence or
absence of the inducing agent (TPA or IgG), and cAMP levels were measured
by ELISA. The intracellular cAMP levels represent the amount of cAMP in 106
cells, and the extracellular levels are expressed as the amount of cAMP in 1 ml
of medium containing 106 cells. Each bar represents the mean  standard
error of the mean of at least two independent experiments. **, P 0.01; ***,
P 0.001.
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treatment, lungs of infected mice showed few inflammatory
cells at day 6 p.i., but numbers of these cells were increased by
day 12 p.i. Enlargement of the MLNs and splenomegaly were
observed in infected mice but not in drug-treated mice. Large,
cell-rich, and poorly delineated follicles, as well as tingible
body macrophages (Fig. 5B, black arrows) were observed in the
spleens of infected mice but were not seen in the spleens of
HPMPC- or HPMP-5-azaC-treated mice.
FIG 5 Analysis of MHV-68 infection in different organs of untreated and treated mice at acute and latent stages of infection. (A) DNA copy numbers were
detected in the lungs, MLNs, and spleens of mice infected by the intranasal route with 104 PFU MHV-68 and treated with HPMPC or HPMP-5-azaC (i.p.) for
5 consecutive days. Each group contained five mice. Results are presented as the mean log viral copy number per mg of tissue the standard deviation. The levels
of MHV-68 gB and ORF73 expression, normalized to the endogenous control, glyceraldehyde-3-phosphate dehydrogenase, were measured relative to the
infected control by using the comparative threshold cycle (CT) method (CT method). Statistical significance was calculated using the Mann-Whitney U test.
*, P 0.05; **, P 0.01. (B) Hematoxylin and eosin staining of lung tissues of uninfected mice, MHV-68-infected mice, HPMPC-treated mice, and HPMP-5-
azaC-treated mice at days 6 and 12 p.i. Histopathology of the spleen at day 12 p.i. is shown in the panels on the right, and arrows indicate the presence of
prominent macrophages in the spleens of infected mice. Magnification,20 (inset,100).
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DISCUSSION
In this report, we evaluated the effects of ANPs, including some
novel derivatives, on the lytic state of gammaherpesvirus replica-
tion. Based on the antiproliferative activity of HPMPC, further
investigations are required to determine whether these com-
pounds also have an effect on KSHV-infected tumor cells or EBV-
transformed cells (24). These studies are of interest since there is a
need for new and potent compounds to clear latently infected cells
to prevent reoccurrence of viral replication. The broad-spectrum
antiviral activities of ANPs depend on the nature of the acyclic side
chain and the base moiety (14). We showed that modification of
the acyclic side chains from a PME group to an HPMP group
resulted in enhancement of antiviral activity against gammaher-
pesviruses, with the exception of MHV-68. In contrast, substitu-
tion of an adenine, as in HPMPA, to a cytosine, as in HPMPC, had
no effect on antigammaherpesvirus activity. In addition, the
5-azacytosine analog showed similar in vitro antiviral potency as
the parent compound, HPMPC. Modification of the adenine base
in HPMPA and PMEA resulted in different profiles of antiviral
activity against gammaherpesviruses. Substitution of the purine
base to a diaminopurine, such as in HPMPDAP, caused a signifi-
cant decrease in anti-EBV, anti-HVS, and anti-RRV activities but
did not modulate the activities against KSHV or MHV-68. In con-
trast to HPMPDAP, PMEDAP showed slightly higher activity
against gammaherpesviruses than PMEA. The diaminopyrimi-
dine counterpart HPMPO-DAPy possessed a slightly decreased
inhibitory activity against gammaherpesviruses (except for MHV-
68) compared to HPMPDAP. The inhibitory effects of PMEO-
DAPy on EBV, KSHV, and MHV-68 replication were comparable
to those of PMEDAP; however, PMEO-DAPy had lower potency
against HVS and RRV (Table 1 and Table 2). The divergent anti-
gammaherpesvirus activities of particular ANPs, mostly adenine
derivatives, could not be linked to the genetic relationship among
the gammaherpesviruses tested. Hence, this study highlights the
requirement of different animal gammaherpesviruses, such as
MHV-68, HVS, and RRV, for antiviral susceptibility testing, in
addition to KSHV and EBV, in order to consider the viruses ap-
propriate surrogate viruses for drug-related studies.
Cyclic prodrugs of ANPs, including cyclic HPMPC and cyclic
HPMPA, have been described to possess similar activities as their
noncyclic forms when evaluated against alpha- and betaherpesvi-
ruses, i.e., herpes simplex virus type 1 (HSV-1), HSV-2, varicella-
zoster virus, and human cytomegalovirus (36). Previously, Lin
and colleagues investigated the inhibitory effects of HPMPA and
cyclic HPMPA on the replication of EBV in P3HR-1 cells (21).
They reported that cyclic HPMPA showed a 19-fold decrease in
anti-EBV activity compared to HPMPA. Remarkably, in our study
not only cyclic HPMPA but also all cyclic HPMP derivatives, with
the exception of cyclic HPMP-5-azaC, showed consistently di-
minished inhibitory effects on EBV replication in P3HR-1 cells
compared to their parent compounds (ranging from 10- to 50-
fold increases in EC50s). On the contrary, we did not observe dif-
ferences in antiviral activities of these compounds against the EBV
Akata strain. These antiviral data agree with our finding that the
induced P3HR-1 cells, but not the induced Akata cells, showed
reduced HPMPC incorporation into cellular DNA when incu-
bated with cyclic HPMPC compared to HPMPC. Of note, dimin-
ished anti-MHV-68 activities were also observed for the cyclic
prodrugs of 7-deaza-HPMPA, HPMPDAP, and HPMPO-DAPy,
in comparison with their parent drugs (Table 2), and these find-
ings must be further investigated to explain the differences in anti-
MHV-68 activities.
Diminished incorporation of HPMPC in induced P3HR-1
cells treated with cyclic HPMPC was the direct consequence of an
altered metabolism of cyclic HPMPC compared to HPMPC in this
cell line. The activation of HPMPC and cyclic HPMPC is the net
result of different processes that involve drug uptake, intracellular
hydrolysis of cyclic HPMPC, intracellular phosphorylation of
HPMPC, and efflux of cyclic HPMPC and/or HPMPC from the
cells (15). Interestingly, we observed that in induced P3HR-1 cells,
cyclic HPMPC was less efficient (than HPMPC) in delivering
HPMPC metabolites, including HPMPCpp, the active form that
leads to DNA incorporation. In induced Akata cells, HPMPC and
cyclic HPMPC had comparable metabolism and, consequently,
similar levels of drug incorporation into cellular DNA. The differ-
ent behaviors between the P3HR-1 and Akata cells were only ob-
served after virus induction, since the latently infected cells showed a
similar metabolic profile when exposed to the compounds. Thus, we
demonstrated an enhanced ability of P3HR-1 cells to metabolize
HPMPC after induction of the EBV lytic cycle, but a decreased ability
to metabolize cyclic HPMPC compared to Akata cells.
The reduced concentrations of HPMPC and its phosphory-
lated metabolites in induced P3HR-1 cells incubated with cyclic
HPMPC suggested that these cells display impaired conversion of
cyclic HPMPC into HPMPC. It was previously reported that this
conversion is mediated by the intracellular cyclic CMP phos-
phodiesterase CNP (37). In the current study, we demonstrated
that induction of EBV replication in P3HR-1 cells did not lead to
an absence or diminished expression of CNP. The enzyme was
equally expressed in different B-cell lines and, in addition, its ex-
pression was independent from the virus that reactivated it (EBV
or KSHV), as well as from the inducing agent (TPA or IgG). The
enzymatic activity of CNP was not considered to be affected by the
Q207R substitution that we identified in the CNP gene of P3HR-1
cells, since this mutation was previously described as a genetic poly-
morphism. Hence, the reduced capacity for CNP-mediated hydroly-
sis of cyclic HPMPC appears not be an intrinsic feature of the P3HR-1
cells. Thus, other factors, such as altered competition with natural
CNP substrates (i.e., cAMP and cCMP), may be involved.
Infections with viruses such as HSV are known to alter the
intracellular levels of cyclic nucleotides, such as decreases in cAMP
levels (38). We observed that latently infected P3HR-1 cells con-
tain notably higher levels of cAMP than other gammaherpes-
virus-infected B cells. Previously, high cAMP levels were asso-
ciated with maintenance of viral latency in Burkitt’s lymphoma
cells (39). The contribution of the cAMP/protein kinase A sig-
naling pathway in EBV latency was attributed to inhibition of
the transactivating immediate-early gene BZLF-1, as well as to
regulation of the activity and transcription of the latency C
promoter (Cp) (39–41). Cp drives the transcription of six
EBNA genes and is active in the EBV type III latency program,
such as in the EBV P3HR-1 strain, but inactive in the EBV type
I latency program (expressing only EBNA1), such as in the EBV
Akata strain (42). Thus, activation and stimulation of Cp are
important to control the expression of the different latency
programs in EBV-infected cells, and this promoter is regulated
by viral and cellular factors, such as cAMP.
Because of the inhibitory effect of cAMP on EBV replication in
P3HR-1 cells, cAMP levels might need to be reduced in order for
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the virus to replicate more efficiently. Indeed, rapid cAMP degra-
dation was triggered upon EBV reactivation. Reduction of intra-
cellular cAMP levels is accomplished by its export across the
plasma membrane, as well as by phosphodiesterase-mediated deg-
radation (43). Since we were not able to correlate the decrease in
intracellular cAMP to an increase of cAMP efflux in P3HR-1 cells,
degradation by phosphodiesterases is most likely responsible for
the rapid elimination of cAMP in these cells. Also, we do not
exclude an indirect effect of TPA treatment on cAMP levels, since
phorbol esters have been shown to influence cAMP phosphodies-
terase activities in certain cell types through activation of protein
kinase C (44).
Taken together, these data strongly indicate that the increased
conversion of cAMP in induced P3HR-1 cells could competitively
counteract cyclic HPMPC hydrolysis by CNP (Fig. 6). Mendel et
al. showed that cAMP, cCMP, and cyclic HPMPC compete with
each other for the active site of this enzyme and that the catalytic
efficiency is 10- to 20-fold higher for cAMP and cCMP than for
cyclic HPMPC (37). Additionally, we may assume that the cyclic
forms of other ANPs, cAMP and cCMP analogs, are also hydro-
lyzed by cAMP- and/or cCMP-converting phosphodiesterases be-
sides CNP. Moreover, P3HR-1 cells are derived from the Jijoye cell
line and, in contrast to Jijoye cells, P3HR-1 cells carry a deletion in
the EBV genome. We can speculate that the presence of this mu-
tation might also influence the metabolism of cyclic prodrugs.
While it was not investigated here, additional studies with Jijoye
cells might help to clear this point.
Cyclic HPMP-5-azaC was the only cyclic HPMP derivative
for which the antiviral activity against EBV in P3HR-1 cells was
comparable to that of the noncyclic form. Interestingly,
HPMP-5-azaC is known to possess a different pharmacologic
profile than HPMPC, since HPMP-5-azaC displays markedly
higher phosphorylation to its active metabolite and higher con-
secutive incorporation into DNA (33). Although diminished
conversion of cyclic HPMP-5-azaC in P3HR-1 cells might also
occur, this might be compensated by the efficient activation of
HPMP-5-azaC, leading to higher incorporation of HPMP-5-
azaC into DNA at levels comparable to those of cyclic HPMPC
and other HPMP derivatives.
We also demonstrated that, in vivo, HPMP-5-azaC has com-
parable anti-MHV-68 efficacy as HPMPC. MHV-68 replication
was greatly reduced in the lungs of infected mice treated i.p. with
HPMPC or HPMP-5-azaC. Although drug treatment was only
effective against the lytic cycle of the virus, ongoing productive
replication is essential for maintaining high levels of latently in-
fected cells. In line with this, levels of the ORF73 transcript were
markedly reduced in drug-treated mice. Until 12 days p.i.,
MHV-68 did not spread from the lungs to other organs, such as
MLNs and spleens, in the mice treated with HPMPC or HPMP-
5-azaC. This prolonged effect may be attributed to the long intra-
cellular half-life of some ANP metabolites, such as the choline
adducts of the cytosine derivatives (33, 45). In this report, we
focused on the efficacy of HPMP-5-azaC to inhibit (i) virus repli-
cation in the lungs and (ii) establishment of latent infection in the
spleen, rather than on the progression of infection during long-
term latency. As virus still resides in the lungs of drug-treated
mice, we expect MHV-68 to reactivate at later time points. Similar
observations were made in previous studies that examined the
efficacy of HPMPC or nucleoside analogs (45, 46).
In conclusion, we have performed a comprehensive investi-
gation of the antigammaherpesvirus activity of several novel
ANPs. HPMPC, HPMP-5-azaC, 3-deaza-HPMPA, and their
cyclic derivatives emerged as the most potent antigammaherpesvirus
agents. Additionally, we observed that cyclic HPMP derivatives have
reduced anti-EBV activities in induced P3HR-1 cells, and this effect
appeared to be specific for this EBV-infected cell line. Our findings
further suggested that the regulation of the different virus latency
patterns and reactivation among two EBV-infected cell lines
might be indirectly involved in the altered metabolism of cyclic
HPMPC and likely of other cyclic prodrugs. Finally, the in vitro
and in vivo data presented here demonstrate that HPMP-5-azaC
may be an attractive candidate for the development of antigam-
maherpesvirus drugs and of DNA viruses in general.
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